Market Overview

Kaleido Biosciences Announces Appointment of Alison Lawton as Chief Executive Officer

Share:

Joshua Brumm to Serve as Chief Operating Officer and Chief Financial
Officer

Michael Bonney Continues Leadership Role as Executive Chairman

Kaleido
Biosciences
, a clinical-stage healthcare company leading the
development of novel chemistries that drive functions of the microbiome
organ, today announced that Alison Lawton, Kaleido's president and chief
operating officer (COO), has been appointed to succeed Michael Bonney as
chief executive officer. Joshua Brumm has been promoted to COO and will
continue to serve as Kaleido's chief financial officer. In addition, Mr.
Bonney will maintain a leadership role at Kaleido as executive chairman
of the Board of Directors.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180821005597/en/

Alison Lawton (Photo: Business Wire)

Alison Lawton (Photo: Business Wire)

"One of my top priorities when I joined Kaleido was to build an
exceptional team with broad and deep experience to lead a rapidly
advancing organization such as ours," said Mr. Bonney. "In the three
years since our inception, we have generated a library of more than 700
novel compounds, conducted seven human clinical studies with our
Microbiome Metabolic Therapies, and raised $165 million, including our
recent Series C financing. We are also well positioned to initiate Phase
2 clinical studies planned for 2019. With all that we have accomplished,
I believe this is the ideal time for Alison to become CEO while I
maintain my commitment to the company as executive chairman. Alison and
Josh are both proven leaders who bring tremendous energy and expertise
to Kaleido, and I look forward to continuing to work with them. They
will be instrumental in ensuring Kaleido realizes the exciting potential
of our revolutionary approach to leveraging the microbiome to treat
disease and improve human health."

Mr. Bonney will remain actively involved in the company, continuing to
chair the Board of Directors and supporting Ms. Lawton and the
leadership team, focusing on long-term business strategy, talent
development and engaging with external stakeholders. Ms. Lawton has more
than 30 years of experience in a range of executive and operating roles
in the biopharmaceutical industry and has served as Kaleido's president
and COO since December 2017. In addition to her role as CEO, she has
been appointed to the company's Board of Directors.

"We are thrilled to have someone with Alison's experience and leadership
skills as CEO of Kaleido and fortunate to have Josh taking on an
expanded role with the company," said Noubar Afeyan, co-founder and
member of Kaleido's Board of Directors and chief executive officer of
Flagship Pioneering. "We look forward to our continued partnership with
Mike and the expanded team during the next phase of growth for this
pioneering company."

"I am honored to have the opportunity to lead Kaleido at an important
time in its evolution," said Ms. Lawton. "We are advancing a robust
pipeline in several disease areas, transforming product development and
building an organization committed to fostering a strong culture. We
have the potential to make an extraordinary impact on patients' lives
and offer solutions that address needs across the healthcare continuum.
I am excited to continue to work with our strong leadership team and
dedicated employees to enhance our science, technology and platform to
lead a revolution in human health."

Prior to joining Kaleido, Ms. Lawton was COO at Aura Biosciences, and
she previously held the same role at OvaScience in 2013. She spent more
than 20 years at Genzyme Corporation and Genzyme Sanofi. She served as
Senior Vice President and General Manager of Sanofi (Genzyme)
Biosurgery, where she was responsible for the surgical, cell therapy and
regenerative medicine, and orthopedics franchises. Earlier, as SVP of
Global Market Access for Genzyme, Ms. Lawton was involved in leading
global functional organizations, including regulatory affairs and
quality systems, public policy, health outcomes and strategic pricing,
product safety and risk management. Additionally, Ms. Lawton worked
for seven years in the U.K. at Warner-Lambert/Parke-Davis. She
previously served two terms as the industry representative on the Food &
Drug Administration's Cell & Gene Therapy Advisory Committee. She
currently serves on the Board of Directors at ProQR Therapeutics
and Verastem, Inc., and was previously a director on the boards of
Cubist Pharmaceuticals, CoLucid Pharmaceuticals, and Magenta
Therapeutics.

Mr. Brumm joined Kaleido as its CFO in April 2018 and will continue to
oversee finance in this capacity. In his new role as COO, he will also
lead commercial, business development, investor relations, information
technology, and facilities. Prior to joining Kaleido, Mr. Brumm was COO
and CFO at Versartis, where he oversaw the company's financial strategy,
including the successful completion of a $145 million initial public
offering, played an integral role in product strategy, and helped
negotiate the company's first product partnership. Prior to that, he was
executive vice president of finance and principal financial officer at
Pharmacyclics and CFO at ZELTIQ Aesthetics, where he also served in
corporate development and sales roles. Over the course of his career,
Mr. Brumm has raised more than $800 million in equity financings.

About Kaleido Biosciences

Kaleido™ is a clinical-stage healthcare company leading the discovery
and development of novel chemistries that drive functions of the
microbiome organ to treat disease and improve human health. The company
is advancing a robust pipeline of Microbiome Metabolic Therapies™ (MMTs)
across a range of therapeutic areas, including rare genetic
disorders. Kaleido's unique discovery and development model is
redefining traditional R&D, enabling product candidates to advance
rapidly into the clinic, dramatically reducing time and cost. Founded in
2015 by Flagship Pioneering, Kaleido has received approximately $165
million to date from its founder and a number of leading investors,
including a wholly-owned subsidiary of the Abu Dhabi Investment
Authority (ADIA), Fidelity Management and Research Company, Invus, and
Rock Springs Capital. Learn more at https://kaleido.com/.

View Comments and Join the Discussion!